These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 22142620)
1. Extreme all-cause mortality in JUPITER requires reexamination of vital records. Serebruany VL Cardiology; 2011; 120(2):84-8. PubMed ID: 22142620 [TBL] [Abstract][Full Text] [Related]
2. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ; Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900 [TBL] [Abstract][Full Text] [Related]
3. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
4. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Kones R Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829 [TBL] [Abstract][Full Text] [Related]
5. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study. Fonseca FA; Izar MC Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857 [TBL] [Abstract][Full Text] [Related]
6. A tale of three labels: translating the JUPITER trial data into regulatory claims. Ridker PM Clin Trials; 2011 Aug; 8(4):417-22. PubMed ID: 21835857 [TBL] [Abstract][Full Text] [Related]
7. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin). O'Keefe JH; Carter MD; Lavie CJ; Bell DS Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548 [TBL] [Abstract][Full Text] [Related]
8. The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction? Sgueglia GA; Crea F J Cardiovasc Med (Hagerstown); 2011 Jan; 12(1):66-70. PubMed ID: 21139510 [TBL] [Abstract][Full Text] [Related]
9. The JUPITER Trial: responding to the critics. Ridker PM; Glynn RJ Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837 [No Abstract] [Full Text] [Related]
10. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ; Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365 [TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels. Carter NJ Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831 [TBL] [Abstract][Full Text] [Related]
12. [The JUPITER study: critical review of final results]. Urbinati S; Romanazzi S; Gambetti S G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):28S-32S. PubMed ID: 21298859 [TBL] [Abstract][Full Text] [Related]
13. The JUPITER trial: How will it change clinical practice? Watson KE Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Hsia J; MacFadyen JG; Monyak J; Ridker PM J Am Coll Cardiol; 2011 Apr; 57(16):1666-75. PubMed ID: 21492764 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. Michos ED; Blumenthal RS J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922 [TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention. López A; Wright JM Int J Occup Environ Health; 2012; 18(1):70-8. PubMed ID: 22550699 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G; Maggioni AP Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394 [TBL] [Abstract][Full Text] [Related]
18. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. Stewart RA Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039 [TBL] [Abstract][Full Text] [Related]
19. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986 [TBL] [Abstract][Full Text] [Related]
20. Another look at the results of the JUPITER trial. Kappagoda CT; Amsterdam EA Am J Cardiol; 2009 Dec; 104(11):1603-5. PubMed ID: 19932800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]